Wilson Sonsini Goodrich & Rosati and Goodwin Procter advised Graphite Bio on the deal. Graphite Bio, Inc., a clinical-stage, next-generation gene editing company focused on therapies...
Graphite Bio’s $238 Million Initial Public Offering
4D pharma plc’s Merger with Longevity Acquisition Corporation
Wilson Sonsini Goodrich & Rosati and Pinsent Masons advised 4D pharma plc on the deal. 4D pharma plc, a Leeds, UK-based pharmaceutical company leading the development...